Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Drops By 59.5%

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 9,877 shares, a decrease of 59.5% from the December 31st total of 24,394 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 70,169 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 70,169 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are short sold.

Institutional Investors Weigh In On OnKure Therapeutics

Several hedge funds have recently modified their holdings of OKUR. XTX Topco Ltd purchased a new stake in shares of OnKure Therapeutics during the 2nd quarter worth approximately $25,000. Bailard Inc. acquired a new stake in OnKure Therapeutics in the second quarter valued at $34,000. Rangeley Capital LLC purchased a new position in shares of OnKure Therapeutics in the second quarter valued at $71,000. GSA Capital Partners LLP raised its stake in shares of OnKure Therapeutics by 172.1% during the 3rd quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after buying an additional 37,459 shares during the last quarter. Finally, Prosight Management LP boosted its position in shares of OnKure Therapeutics by 67.8% in the 3rd quarter. Prosight Management LP now owns 267,959 shares of the company’s stock worth $737,000 after buying an additional 108,267 shares in the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Wall Street Zen raised shares of OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $32.00.

OnKure Therapeutics Trading Down 3.3%

OKUR stock traded down $0.09 on Friday, hitting $2.64. The company’s stock had a trading volume of 69,927 shares, compared to its average volume of 67,208. The stock has a market cap of $35.77 million, a price-to-earnings ratio of -0.55 and a beta of 0.47. The firm has a 50 day moving average of $2.94 and a two-hundred day moving average of $2.78. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $6.48.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.11. As a group, equities analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.